Fulminant demyelinating encephalomyelitis
Insights from antibody studies and neuropathology
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 28, 2015
- Accepted in final form September 18, 2015
- First Published November 4, 2015.
Author Disclosures
- Franziska Di Pauli, MD,
- Romana Höftberger, MD,
- Markus Reindl, PhD,
- Ronny Beer, MD,
- Paul Rhomberg, MD,
- Kathrin Schanda, MSc,
- Douglas Sato, MD,
- Kazuo Fujihara, MD,
- Hans Lassmann, MD,
- Erich Schmutzhard, MD and
- Thomas Berger, MD
- Franziska Di Pauli, MD,
NONE
NONE
Biogen idec, funding for travel to conference and speaker honoraria Genzyme, funding for travel to conference and speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romana Höftberger, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Reindl, PhD,
NONE
NONE
NONE
PLOS ONE, academic editor, 2012-Current Medicinal Chemistry, editorial board, 2006-2012 Autoimmune Diseases, 2012-2013
NONE
NONE
NONE
NONE
NONE
The University Hospital and Medical University of Innsbruck (Austria, Markus Reindl) receive payments for antibody assays (NMDAR, AQP4 and other autoantibodies) and for AQP4 antibody validation experiments organized by Euroimmun.
NONE
NONE
(1) This study was supported by a research grant from the Austrian Federal Ministery of Science and Economy (grant BIG WIG MS).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ronny Beer, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Austrian Science Fund, KLI 375-B00, Principal Investigator, 2014-2016.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paul Rhomberg, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrin Schanda, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Douglas Sato, MD,
NONE
NONE
Speaker honoraria from Novartis
Associate editor of Arquivos de Neuropsiquiatria (2013-present)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Ministry of Education, Culture, Sports, Science & Technology (MEXT) in Japan, Japanese Government Scholarship Program, 4 years (2010 - 2014)
NONE
(1) Grant-in-aid for scientific research from the Japan Society for the Promotion of Science (KAKENHI 15K19472) (2) Research support from CAPES/Brasil (88881.068012/2014)
NONE
NONE
NONE
NONE
NONE
NONE
- Kazuo Fujihara, MD,
Serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, Merck Serono, Alexion Pharmaceuticals, Medimmune and Medical Review.
NONE
has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Asahi Kasei Medical Co., Daiichi Sankyo, and Nihon Pharmaceutical.
Serve as an editorial board member of Clinical and Experimental Neuroimmunology (2009-present) and a advisory board member of Sri Lanka journal of Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
has received research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai Pharmaceutical,Ono Pharmaceutical, Nihon Pharmaceutical, and Genzyme Japan.
funded as the investigator (2010?present) by the Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan and as the secondary investigator by the Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labor of Japan (2010?present).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hans Lassmann, MD,
NONE
NONE
I have received speaker and travel honoraria for several scientific meetings from Biogen Idec, Novartis and Teva.
I am member of the Editorial Board of several Journals in the fields of Neurology and Neuroscience.
NONE
NONE
NONE
I have served as a consultant for Biogen Idec and AMGEN.
NONE
NONE
NONE
NONE
Austrian Science Fund, Projects P19854, P 24245;principal investigator; 2007-2012 European Union FP7 Project Neuroprmise Pl 018637 2007-2011; Subproject; E-Rare Project EDEN; 2011-2014; subproject This funding is not directly related to the respective article
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Erich Schmutzhard, MD and
NONE
NONE
UCB and ZOLL Medical: speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Berger, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Clinical Department of Neurology (F.D.P., M.R., R.B., K.S., E.S., T.B.) and Department of Neuroradiology (P.R.), Medical University of Innsbruck; Institute of Neurology (R.H.) and Center for Brain Research (H.L.), Medical University of Vienna, Austria; and Departments of Neurology and Multiple Sclerosis Therapeutics (D.S., K.F.), Tohoku University Graduate School of Medicine, Sendai, Japan.
- Correspondence to Dr. Berger: thomas.berger{at}i-med.ac.at
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014 -
Article
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeletonRussell C. Dale, Esther M. Tantsis, Vera Merheb et al.Neurology - Neuroimmunology Neuroinflammation, May 22, 2014 -
Views & Reviews
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?Scott S. Zamvil, Anthony J. Slavin et al.Neurology - Neuroimmunology Neuroinflammation, January 22, 2015 -
Article
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsyRyo Ogawa, Ichiro Nakashima, Toshiyuki Takahashi et al.Neurology: Neuroimmunology & Neuroinflammation, January 16, 2017